Themis Qi CK Life Sciences (0775) said it will welcome investments for the ongoing development of an analgesic after announcing one of its biotech subsidiaries will merge with a US-listed peer. The drug, Halneuron, is expected to be marketed as early as 2028 to offer a new treatment for chemotherapy-induced... read full story
"CK Life will be glad to have new investors, even though the coming funds will dilute our equity in the Dogwood,"